Driven by patient needs

Severe blood disorders can affect nearly every aspect of a person’s life, from physical health and daily activities to emotional well-being and the ability to plan for the future. While important progress has been made, many people living with these conditions still face significant challenges, including limited treatment options, ongoing symptoms and an enduring impact on quality of life.

At Marrow, we believe people living with severe blood disorders deserve better options. We are focused on developing medicines designed to address the underlying drivers of disease, with the goal of delivering meaningful and lasting benefits for patients. Our commitment extends beyond treating disease to helping improve the overall experience of living with these conditions, for both patients and their caregivers.

Eleanor Lisbon
Vice President, Medical Affairs

“People living with blood disorders continue to face significant unmet needs and deserve access to new therapeutic options. Our team is committed to advancing potential new treatments that could make a meaningful difference for patients and families. Sickle cell disease, which affects millions of individuals worldwide, is one example of where that need remains, and I am proud to be part of the effort to help bring a new treatment option forward.

Marrow is working to develop new treatment options for people living with severe blood disorders, beginning with sickle cell disease and beta thalassemia.

Sickle cell disease affects ~100,000 people in the US and nearly 8 million worldwide, with 80% of cases found in sub-Saharan Africa. The disease is responsible for over 80,000 childhood deaths annually.

Source: Centers for Disease Control and World Health Organization

Sickle cell disease

Disease manifestations

Patients with “sickled” blood cells can experience disease manifestations such as chronic pain, progressive organ damage, increased thrombotic and cardiovascular risk, anemia, swelling, infections, fatigue, stroke, vision problems, reduced lifespan and more.

Treatment challenges

While new treatments have expanded options for people living with sickle cell disease, many patients still face significant symptoms, treatment burdens and challenges accessing therapies that can meaningfully change the course of their disease.

Our approach

We are aiming to address the genetic underpinnings of sickle cell disease through our lead program MAR-101, a novel antibody bioconjugate.

Learn about MAR-101

Beta thalassemia major affects approximately 60,000 newborns each year worldwide, with highest prevalence in Mediterranean countries. Though over 350 genetic mutations can cause the disease, just 20 account for 80% of all cases.

Source: Orphanet Journal of Rare Diseases and Gene

Beta thalassemia

Disease manifestations

Patients with beta thalassemia can experience life-threatening anemia, bone deformities, spleen enlargement, fatigue, weakness and more.

Treatment challenges

Treatment for beta thalassemia can require lifelong management and, for some patients, regular blood transfusions and iron chelation, underscoring the need for therapies that can provide more durable disease control with less treatment burden.

Our approach

Our lead program, MAR-101, is a novel antibody bioconjugate designed to target the genetic driver of beta thalassemia.

Learn about MAR-101